Business
Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch
Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch.
About this update from Odyssey Health Inc.
[{"type":"text","content":"\n IRVINE, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the \"Company\" or \"Odyssey\"), a technology and asset acquisition company focused on developing unique medical products, today announced the successful completion of their novel drug-device combination product to be administered in human clinical trials for treating concussion. After sustaining a concussion there is brain swelling, inflammation and oxidative stress. Odyssey has developed a drug formulation designed to reduce this harmful response. The drug formula can be given via breath propulsion into the nose. As a spray-dried powder formulation, the active drug can be dispersed throughout the upper portion of the nasal cavity without being inhaled or swallowed. The drug-device combination allows for the drug to travel upward along the cranial nerves used for smell and is delivered directly into the traumatized brain. The final powdered formula has been completed and certified by Upperton Limited, a GMP drug manufacturer based in the UK. Particle size to be dispersed from the device has been defined. Upperton is now filling, packaging and labeling the drug-device combination product in preparation for Odyssey’s Phase 1 clinical trial. “By developing our drug formulation in powder form we can ensure all regions of the nasal cavity are exposed thus increasing the amount absorbed into the brain. We believe this novel formulation will not only lead to greater drug efficacy but with our targeted approach reduce exposure and any potential side effects to other organs of the body.” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International. “We are excited that we have been able to optimize and begin manufacturing Odyssey’s concussion drug formula for human trials. Our expertise in manufacturing drugs into spray-dried powder form is used to maximize drug performance and safety. It’s exciting to be involved in such a novel drug administration design.” Said Paul Kelsall, Director of Clinical Manufacturing, Upperton Limited, Inc. About Odyssey Group International, Inc. Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquir...